FDA Working On QT Interval Guidance Under Cardio-Renal’s Throckmorton
Executive Summary
FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is the chair of an agency working group that is attempting to provide clear advice to industry on how to assess drugs that prolong the QT interval
You may also be interested in...
FDA Cardio-Renal Head Throckmorton Moves Up To Acting Deputy Of CDER
FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is moving up to the position of acting deputy director of CDER, effective May 3
FDA Cardio-Renal Head Throckmorton Moves Up To Acting Deputy Of CDER
FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is moving up to the position of acting deputy director of CDER, effective May 3
FDA Rx Risk Assessment Guidance May Detail Lab Test Parameters
FDA's risk assessment working group is considering developing specific recommendations on which lab test results could signal safety problems for drugs under review